History
Okumaya devam et...
← Previous revision | Revision as of 23:24, 19 April 2024 |
| Line 85: | Line 85: |
| In the early 1990s, the first successful gene therapy was used to treat [[severe combined immunodeficiency]] in patient [[Ashanthi DeSilva]]: it employed a recombinant retrovirus.{{sfn|Bulcha|2022|pp=1}} | |
 | Gelsinger joined a clinical trial run by the [[University of Pennsylvania]] that aimed at developing a treatment for infants born with the severe form of the disease. On September 13, 1999, Gelsinger was injected with [[adenoviridae|an adenoviral vector]] carrying a corrected gene to test the safety of the procedure. He died four days later at the age of 18, on September 17, apparently having suffered a massive immune response triggered by the use of the viral vector to transport the gene into his cells, leading to multiple organ failure and brain death.<ref>{{Cite magazine |last=Stolberg |first=Sheryl Gay |date=November 28, 1999 |title=The Biotech Death of Jesse Gelsinger |url=https://www.nytimes.com/1999/11/28/magazine/the-biotech-death-of-jesse-gelsinger.html |magazine=The New York Times Magazine |language=en-US |access-date=July 5, 2018}}</ref> |
| Gelsinger joined a clinical trial run by the [[University of Pennsylvania]] that aimed at developing a treatment for infants born with the severe form of the disease. On September 13, 1999, Gelsinger was injected with [[adenoviridae|an adenoviral vector]] carrying a corrected gene to test the safety of the procedure. He died four days later at the age of 18, on September 17, apparently having suffered a massive immune response triggered by the use of the viral vector to transport the gene into his cells, leading to multiple organ failure and brain death.<ref>{{Cite magazine |last=Stolberg |first=Sheryl Gay |date=November 28, 1999 |title=The Biotech Death of Jesse Gelsinger |url=https://www.nytimes.com/1999/11/28/magazine/the-biotech-death-of-jesse-gelsinger.html |magazine=The New York Times Magazine |language=en-US |access-date=July 5, 2018}}</ref> |
| ==Challenges in application== | ==Challenges in application== |
Okumaya devam et...